Shandong Keyuan Pharmaceutical Co (SZSE:301281) Short-Term Debt: ¥39.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301281 Shandong Keyuan Pharmaceutical Co Ltd SZSE:301281
76 GF Score
Price ¥43.90
GF Value ¥27.85
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Shandong Keyuan Pharmaceutical Co Short-Term Debt?

Shandong Keyuan Pharmaceutical Co SZSE:301281 +7.97% 76 Short-Term Debt is ¥39.4 Mil as of Mar. 2026. GuruFocus rates SZSE:301281 with a GF Score™ of 76/100 and a GF Value™ of ¥27.85 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Shandong Keyuan Pharmaceutical Co's Short-Term Debt for the quarter that ended in Mar. 2026 was ¥39.4 Mil.

Shandong Keyuan Pharmaceutical Co's quarterly Short-Term Debt stayed the same from Sep. 2025 (¥0.0 Mil) to Dec. 2025 (¥0.0 Mil) but then increased from Dec. 2025 (¥0.0 Mil) to Mar. 2026 (¥39.4 Mil).

Shandong Keyuan Pharmaceutical Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Shandong Keyuan Pharmaceutical Co Short-Term Debt Related Terms

Shandong Keyuan Pharmaceutical Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Shandong Keyuan Pharmaceutical Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Keyuan Pharmaceutical Co Short-Term Debt Chart

Shandong Keyuan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Shandong Keyuan Pharmaceutical Co Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.48 0.00 0.00 0.00 39.44
SZSE:301281
76GF Score
Shandong Keyuan Pharmaceutical Co Ltd SZSE:301281
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥39.4 Mil mean?
Shandong Keyuan Pharmaceutical Co (SZSE:301281) has a Short-Term Debt of ¥39.4 Mil as of Mar. 2026.
Is Shandong Keyuan Pharmaceutical Co's Short-Term Debt too high?
Shandong Keyuan Pharmaceutical Co's current Short-Term Debt is ¥39.4 Mil. Overall, Shandong Keyuan Pharmaceutical Co has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Keyuan Pharmaceutical Co's Short-Term Debt compare to LLY and JNJ?
Shandong Keyuan Pharmaceutical Co's Short-Term Debt of ¥39.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Shandong Keyuan Pharmaceutical Co's current Short-Term Debt is ¥39.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Keyuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Keyuan Pharmaceutical Co (SZSE:301281) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥27.85, compared to a current price of ¥43.90 — trading 57.6% above its estimated fair value. The current Short-Term Debt is ¥39.4 Mil. Shandong Keyuan Pharmaceutical Co's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Shandong Keyuan Pharmaceutical Co (SZSE:301281), the current Short-Term Debt is ¥39.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Keyuan Pharmaceutical Co (SZSE:301281) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Keyuan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥43.90 is trading 57.6% above its estimated GF Value™ of ¥27.85. GuruFocus considers Shandong Keyuan Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SZSE:301281:

  • Short-Term Debt: ¥39.4 Mil
  • GF Value™: ¥27.85 vs. price of ¥43.90 (57.6% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the SZSE:301281 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shandong Keyuan Pharmaceutical Co Business Description

Address Keyuan Street, Shandong Shanghe Economic Development Zone, Shandong Province, Jinan, CHN, 251601
Shandong Keyuan Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of chemical raw materials and their preparations.
76GF Score

Get the complete analysis for SZSE:301281

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥43.90
Price
¥27.85
GF Value